Meditation therapies for attention-deficit/hyperactivity disorder (ADHD)

Department of Psychiatry, Faculty of Medicine, KhonKaen University, KhonKaen, Thailand, 40002.
Cochrane database of systematic reviews (Online) (Impact Factor: 5.94). 01/2010; DOI: 10.1002/14651858.CD006507.pub2
Source: PubMed

ABSTRACT Attention-deficit/hyperactivity disorder (ADHD) is one of the most common developmental disorders experienced in childhood and can persist into adulthood. The disorder has early onset and is characterized by a combination of overactive, poorly modulated behavior with marked inattention. In the long term it can impair academic performance, vocational success and social-emotional development. Meditation is increasingly used for psychological conditions and could be used as a tool for attentional training in the ADHD population.
To assess the effectiveness of meditation therapies as a treatment for ADHD.
Our extensive search included: CENTRAL, MEDLINE, EMBASE, CINAHL, ERIC, PsycINFO, C2-SPECTR, dissertation abstracts, LILACS, Virtual Health Library (VHL) in BIREME, Complementary and Alternative Medicine specific databases, HSTAT, Informit, JST, Thai Psychiatric databases and ISI Proceedings, plus grey literature and trial registries from inception to January 2010.
Randomized controlled trials that investigated the efficacy of meditation therapy in children or adults diagnosed with ADHD.
Two authors extracted data independently using a pre-designed data extraction form. We contacted study authors for additional information required. We analyzed data using mean difference (MD) to calculate the treatment effect. The results are presented in tables, figures and narrative form.
Four studies, including 83 participants, are included in this review. Two studies used mantra meditation while the other two used yoga compared with drugs, relaxation training, non-specific exercises and standard treatment control. Design limitations caused high risk of bias across the studies. Only one out of four studies provided data appropriate for analysis. For this study there was no statistically significant difference between the meditation therapy group and the drug therapy group on the teacher rating ADHD scale (MD -2.72, 95% CI -8.49 to 3.05, 15 patients). Likewise, there was no statistically significant difference between the meditation therapy group and the standard therapy group on the teacher rating ADHD scale (MD -0.52, 95% CI -5.88 to 4.84, 17 patients). There was also no statistically significant difference between the meditation therapy group and the standard therapy group in the distraction test (MD -8.34, 95% CI -107.05 to 90.37, 17 patients).
As a result of the limited number of included studies, the small sample sizes and the high risk of bias, we are unable to draw any conclusions regarding the effectiveness of meditation therapy for ADHD. The adverse effects of meditation have not been reported. More trials are needed.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This is an ongoing project. Special thanks to Christopher Germer, Ph.D. and the Institute for Meditation and Psychotherapy for their many contributions. This bibliography does not try to include all the references to the broader Buddhist/therapy dialogue, which would extend it considerably. Also, more complete references for mindfulness in relation to physical and medical conditions, as well as neuroscience and physiological effects of mindfulness can be found in John C. Williams and Lidia Zylowska's "Mindfulness Bibliography. From molecules to mindfulness: Howe vertically convergent fractal time fluctuations unify cognition and emotion. Consciousness & Emotion, 1, 193-226.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abnormal dopamine (DA) transporter functioning has long been suspected to be involved in attention-deficit hyperactivity disorder (ADHD). My extensive search on theories concerning ADHD included: CENTRAL, MEDLINE, EMBASE, CINAHL, ERIC, PsycINFO, Complementary and Alternative Medicine-specific databases, Informit, JST, plus grey literature and trial registries from inception to May 2010. A new understanding of ADHD pathophysiology is required. DA-deficit theory of ADHD is insufficient to cover critical aspects of ADHD pathology and medication. The dominance of this theory discourages the human and financial investments needed to explore alternative theories and has caused an evident bias in health and drug policies. A combined theory of altered DA and serotonin (5HT), deficit DA, and weakened prefrontal cortex (PFC) circuits may serve as a good alternate to DA-theory alone. This combined theory may influence the future of drug polices, pharmaceutical investments, treatment options, and drug developments.
    ADHD Attention Deficit and Hyperactivity Disorders 11/2010; 2(3):149-57. DOI:10.1007/s12402-010-0033-z
  • [Show abstract] [Hide abstract]
    ABSTRACT: Physiological differences between children and adults result in age-related differences in pharmacokinetics and drug effect. In neonates and infants, decreased weight-adjusted doses are required because of decreased protein binding, renal excretion, and/or metabolism. For children older than 1 year of age, significantly higher weight-corrected doses compared with adults are needed for drugs eliminated by the cytochrome P450 (CYP) isozymes CYP1A2, CYP2C9, and CYP3A4. In contrast, weight-corrected doses for drugs eliminated by renal excretion or metabolism by CYP2C19, CYP2D6, N-Acetyl-transferase, and UDP glucuronosyltransferase in children are similar to those in adults. Ideally, pharmacokinetic and pharmacodynamic data should be available for all drugs used in children. Because many drugs are not approved for pediatric use, data are often limited, especially for older drugs. Understanding the effects of age on pharmacokinetics can help to determine appropriate pediatric dosing in situations in which there is limited information.
    Seminars in pediatric neurology 12/2010; 17(4):208-13. DOI:10.1016/j.spen.2010.10.002 · 1.88 Impact Factor


Available from